Amber Walker
Acute Care · Boaz, ALNPI 1811448202
Payments from drug & device makers
Across 135 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$301
- AstraZeneca$291
- AbbVie$279
- Bayer$196
- Merck$168
- Ironshore Pharmaceuticals Inc.$163
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,537100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $301 |
| AstraZeneca | 15 | $291 |
| AbbVie | 14 | $279 |
| Bayer | 13 | $196 |
| Merck | 9 | $168 |
| Ironshore Pharmaceuticals Inc. | 9 | $163 |
| Dexcom, Inc. | 8 | $140 |
| Novartis | 7 | $115 |
| Lundbeck LLC | 3 | $75 |
| Phathom Pharmaceuticals, Inc. | 4 | $73 |
| Novo Nordisk | 5 | $71 |
| Amarin Pharma, Inc. | 3 | $66 |
| Lilly USA, LLC | 4 | $61 |
| Boston Scientific | 3 | $53 |
| Amgen | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Johnson & Johnson | 2 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Gilead | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Ardelyx, Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
How this compares
$2,537 in reported general payments places this provider in the 80th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 135 | $162,109 |
| OzempicSemaglutide | 90 | $116,645 |
| JardianceEmpagliflozin | 76 | $102,607 |
| EliquisApixaban | 85 | $93,763 |
| TrulicityDulaglutide | 81 | $87,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $55,295 |
| FarxigaDapagliflozin Propanediol | 40 | $41,192 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $35,714 |
| XareltoRivaroxaban | 17 | $26,803 |
| VascepaIcosapent Ethyl | 33 | $26,791 |
| LinzessLinaclotide | 22 | $25,222 |
| JanuviaSitagliptin Phosphate | 17 | $24,602 |
| MyrbetriqMirabegron | 24 | $22,842 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $21,481 |
| Repatha SureclickEvolocumab | 25 | $21,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $61 | $249,891216 claims |
| Novo NordiskOzempic | $71 | $116,64590 claims |
| Boehringer IngelheimJardiance | $36 | $102,60776 claims |
| PfizerEliquis | $13 | $93,76385 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $301 | $76,777105 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $291 | $54,78558 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $40 | $35,71435 claims |
| Johnson & JohnsonXarelto | $38 | $26,80317 claims |
| AbbVieLinzess | $279 | $25,22222 claims |
| MerckJanuvia | $168 | $24,60217 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $22,84224 claims |
| NovartisEntresto | $115 | $17,04711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 711 acute care providers in Alabama.
Other acute care in Boaz
- Paige HarrisMontgomery$465K
- Coretta CollinsBirmingham$77K
- Debra DavisFoley$31K
- Leslie GastonMobile$22K
- Gwendolyn HooperTuscaloosa$16K
- Rachel PrytulaDothan$14K
- Jennifer UmbargerMobile$14K
- April KlarHuntsville$13K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.